Asston Pharmaceuticals Ltd

Asston Pharmaceuticals Ltd has announced a Board Meeting scheduled for Thursday, July 2, 2026. The primary agenda is to consider proposals for raising funds through various methods, including a preferential issue, subject to regulatory and shareholder approvals. In line with SEBI regulations and the company's code of conduct, the trading window for the company's securities will be closed from June 24, 2026, to July 4, 2026, inclusive. All connected and designated persons are advised against trading during this period.

Asston Pharmaceuticals Ltd has announced a Board of Directors meeting scheduled for July 2, 2026. The primary agenda item is to consider and approve proposals for raising funds through various methods, including preferential issue, subject to necessary regulatory and shareholder approvals. Additionally, the company will close its trading window from June 24, 2026, to July 4, 2026, to prevent insider trading during this period. All connected and designated persons are advised against trading in the company's securities during the window closure.

Asston Pharmaceuticals Ltd has announced its audited financial results for the year ended March 31, 2026. The Board of Directors approved the financial statements and results during a meeting held on May 29, 2026. The audit report, conducted by Panchal S K & Associates, provides an opinion that the financial results present a true and fair view in accordance with regulatory requirements and accounting standards.

Asston Pharmaceuticals Ltd. announced the approval of its audited financial results for the financial year ended March 31, 2026, during a Board of Directors meeting held on May 29, 2026. The meeting, conducted via video conferencing, commenced at 03:00 P.M. and concluded at 07:10 P.M. The approved financial statements and results, along with the audit report, comply with Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Panchal S K & Associates, Chartered Accountants, conducted the independent audit, expressing an opinion that the financial results present a true and fair view in accordance with applicable accounting standards.

Asston Pharmaceuticals Ltd's Board of Directors approved the audited financial statements and financial results along with the audit report for the financial year and half year ended March 31, 2026, during their meeting held on May 29, 2026. The meeting, conducted via video conferencing, commenced at 03:00 P.M. and concluded at 07:10 P.M. The auditors, Panchal S K & Associates, have issued an independent auditor's report stating that the financial results present a true and fair view in conformity with accounting standards.

Asston Pharmaceuticals Ltd has scheduled a Board of Directors meeting on May 29, 2026, to consider and approve the audited financial statements and financial results for the financial year and quarter ended March 31, 2026. The board will also review the statement of deviation of funds as per SEBI regulations.

Asston Pharmaceuticals Ltd. has announced an Extraordinary General Meeting to be held on 28th April, 2026. The meeting will be conducted through 'Vide Conferencing' or 'Other Audio Visual Means'. The Company has arranged for an e-voting facility for its members and the cut-off date for determining the eligibility to vote has been fixed as April 17th, 2026. The meeting will transact two main businesses: the appointment of M/s Panchal SK & Associates as statutory auditors and the regularization of Mr. Yogesh Prakash Supekar as a Non-Executive Non-Independent Director.

Asston Pharmaceuticals Ltd has announced the record date for the E-voting process for its Extraordinary General Meeting (EGM) scheduled on 28th April, 2026. The record date has been fixed as 17th April, 2026. The EGM will be held through 'Vide Conferencing' or 'Other Audio Visual Means'. The company has arranged for an e-voting facility for its members from National Securities Depository Limited (NSDL). The e-voting will start on 23rd April, 2026, at 09:00 AM and end on 27th April, 2026, at 05:00 PM. The cut-off date for determining the eligibility to vote by electronic means or in the EGM has been fixed as April 17th, 2026.

Asston Pharmaceuticals Ltd has announced new appointments in its management team. Mr. Sumit Pawar has been appointed as the Chief Financial Officer, Mr. Yashvardhan Tupe as Additional Non-Executive Director, and Mr. Sandip Sharma as Additional Non-Executive Independent Director. The appointments were approved at the Board of Directors meeting held on 30th March, 2026. The company also announced the date of the Extraordinary General Meeting, scheduled to be held on 28th April, 2026.

Asston Pharmaceuticals Ltd has announced the appointment of Mr. Sumit Pawar as Chief Financial Officer, Mr. Yashvardhan Tupe as Additional Non-Executive Director, and Mr. Sandip Sharma as Additional Non-Executive Independent Director, all effective from 30th March, 2026. The company has also approved the date for the Extraordinary General Meeting (EGM) scheduled on 28th April, 2026.